Figure 1
From: Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen
Strategy to assess different FP sequences and carrier proteins for their capacity to elicit HIV-neutralizing responses. (a) Schematic of experimental design. Fusion peptides are conjugated to carrier proteins (left) to elicit antibodies with cross-clade breadth (shown on a neutralization dendrogram for the FP-directed murine antibody vFP16.022). (b) Prevalent FP sequences. FP sequence frequencies were calculated based on the N-terminal six or eight residues in the LANL HIV database34. (c) Properties of carrier proteins commonly used in conjugate vaccines. (d) Combination of 4 FP sequences with 4 carrier proteins to obtain 16 FP-carrier protein conjugates. Fusion peptides were synthesized with a C-terminal Cys to be coupled to the exposed Lys on the carrier proteins through a bi-functional linker. The four most prevalent FP sequences in (b) were chosen to have a wide coverage of HIV strains.
